Halda Therapeutics secures $126 million financing

Connecticut, USA-based biotech start-up Halda Therapeutics announced that it has raised new financing of $126 million in a Series B extension.

Including this financing, Halda, which is developing a novel class of cancer therapies called RIPTAC (regulated induced proximity targeting chimeras) therapeutics, has raised $202 million to date from investors, said Halda, which emerged from stealth a year and a half ago.

New investors included Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital and Taiho Ventures, adding to existing investors Canaan Partners, Access Biotechnology, Elm Street Ventures, and Connecticut Innovations.